Deutsch English Français

Contact

EP1946118

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP1946118

EP1946118 - TISSUE DIAGNOSTICS FOR BREAST CANCER [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 09.10.2009 Database last updated on 20.07.2024
Most recent event Tooltip	08.01.2010	Change - previously filed application	published on 10.02.2010 [2010/06]
Applicant(s)	For all designated states Aurelium Biopharma Inc. 8475 Christophe-Colomb Avenue, Suite 1000 Montreal Quebec City H2M 2N9 / CA
	[2008/30]
Inventor(s)	01 / GEORGES, Elias 2095 De Vouvray Laval, Quebec H7M 3J7 / CA
	02 / LANTHIER, Julie 8475 Christophe-Colomb Avenue SUITE 1000 Montreal, Quebec, H2M 2N9 / CA
	03 / BOUCHER, Claudia 86 De L'Arche Ile Perrot, Quebec J7V 7P2 / CA
	04 / BONNEAU, Anne-Marie 2095 De Vouvray Laval, Quebec H7M 3J7 / CA
	[2008/30]
Representative(s)	Grund, Martin Grund Intellectual Property Group Patentanwälte und Solicitor PartG mbB Steinsdorfstraße 2 80538 München / DE
	[N/P]
Former [2008/30]	Grund, Martin Grund Intellectual Property Group Nikolaistrasse 15 80802 München / DE
Application number, filing date	06851248.2	09.11.2006
	[2008/30]
	WO2006IB04269
Priority number, date	US20050735477P	10.11.2005 Original published format: US 735477 P
	US20060802044P	18.05.2006 Original published format: US 802044 P
	[2008/30]
Previously filed application, date	WO2006IB04269	09.11.2006
	[2010/06]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2007141595
	Date:	13.12.2007
	Language:	EN
	[2007/50]
	Type:	A2 Application without search report
	No.:	EP1946118
	Date:	23.07.2008
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 13.12.2007 takes the place of the publication of the European patent application.
	[2008/30]
Search report(s)	International search report - published on:	CA	17.04.2008
	(Supplementary) European search report - dispatched on:	EP	19.12.2008
Classification	IPC:	G01N33/574, G01N33/50	[2008/30]
	CPC:	G01N33/57415 (EP,US); G01N2333/4742 (EP,US); G01N2333/705 (EP,US); G01N2333/912 (EP,US); G01N2333/96472 (EP,US)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2008/30]
Extension states	AL	Not yet paid
	BA	Not yet paid
	HR	Not yet paid
	MK	Not yet paid
	RS	Not yet paid
Title	German:	GEWEBEDIAGNOSE FÜR BRUSTKREBS	[2008/30]
	English:	TISSUE DIAGNOSTICS FOR BREAST CANCER	[2008/30]
	French:	DIAGNOSTIC TISSULAIRE DU CANCER DU SEIN	[2008/30]
Entry into regional phase	14.05.2008	National basic fee paid
	14.05.2008	Search fee paid
	14.05.2008	Designation fee(s) paid
	14.05.2008	Examination fee paid
Examination procedure	14.05.2008	Examination requested [2008/30]
	03.07.2008	Amendment by applicant (claims and/or description)
	18.03.2009	Application deemed to be withdrawn, date of legal effect [2009/46]
	19.05.2009	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2009/46]
Divisional application(s)	EP09003767.2 / EP2177910
Fees paid	Renewal fee
	16.03.2009	Renewal fee patent year 03
	Penalty fee
	Additional fee for renewal fee
	30.11.2008	03 M06 Fee paid on 16.03.2009
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[A]WO0018783 (UNIV WASHINGTON [US], et al) [A] 1-16 * page 39, paragraph 2 *;
		[A]WO0052463 (UNIV MISSISSIPPI MEDICAL CENTE [US], et al) [A] 1-16 * claims 1,3 *;
		[A]US2003044859 (HENSLEE JERRY G [US], et al) [A] 1-16 * claim 1 *;
		[A]WO2005028676 (ONCOTHERAPY SCIENCE INC [JP], et al) [A] 1-16 * claims 1,2 *;
		[A]WO2005083440 (UNIV YALE [US], et al) [A] 1-16 * claims 1,12 *;
		[X] - ZHANG DAO-HAI ET AL, "Proteomics of breast cancer: Enhanced expression of cytokeratin 19 in human epidermal growth factor receptor type 2 positive breast tumors", PROTEOMICS, (200505), vol. 5, no. 7, ISSN 1615-9853, pages 1797 - 1805, XP002502158 [X] 1-16 * page 1802, column R, paragraph 2 - page 1803, column L * DOI: http://dx.doi.org/10.1002/pmic.200401069
		[Y] - SHEN D ET AL, "Loss of annexin A1 expression in human breast cancer detected by multiple high-throughput analyses", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, (20041231), vol. 326, no. 1, ISSN 0006-291X, pages 218 - 227, XP004672571 [Y] 1-16 * table 2 * DOI: http://dx.doi.org/10.1016/j.bbrc.2004.10.214
		[Y] - IMYANITOV E N ET AL, "Mechanisms of breast cancer", DRUG DISCOVERY TODAY: DISEASE MECHANISMS, ELSEVIER, (20041101), vol. 1, no. 2, ISSN 1740-6765, pages 235 - 245, XP004654008 [Y] 1-16 * table 1 * DOI: http://dx.doi.org/10.1016/j.ddmec.2004.09.002
		[Y] - ELLIOTT BRUCE E ET AL, "The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells.", BREAST CANCER RESEARCH : BCR 2005, (20050321), vol. 7, no. 3, ISSN 1465-542X, pages R365 - R373, XP002503662 [Y] 1-16 * page R372, column R, paragraphs 2,3 * DOI: http://dx.doi.org/10.1186/BCR1006
		[A] - STATHOPOULOU A ET AL, "MOLECULAR DETECTION OF CANCER CELLS IN THE PERIPHERAL BLOOD OF PATIENTS WITH BREAST CANCER: COMPARISON OF CK-19, CEA AND MASPIN AS DETECTION MARKERS", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS, (20030301), vol. 23, no. 2C, ISSN 0250-7005, pages 1883 - 1890, XP009042662 [A] 1-16 * abstract *
		[A] - GRUENEWALD KURT ET AL, "Mammaglobin gene expression: A superior marker of breast cancer cells in peripheral blood in comparison to epidermal-growth-factor receptor and cytokeratin-19", LABORATORY INVESTIGATION, (200007), vol. 80, no. 7, ISSN 0023-6837, pages 1071 - 1077, XP002502275 [A] 1-16 * the whole document *
		[A] - BACKUS JOHN ET AL, "Identification and characterization of optimal gene expression markers for detection of breast cancer metastasis", JOURNAL OF MOLECULAR DIAGNOSTICS, (200508), vol. 7, no. 3, ISSN 1525-1578, pages 327 - 336, XP002502276 [A] 1-16 * table 3 *
		[A] - CHATTERJEE S K ET AL, "Cancer biomarkers: knowing the present and predicting the future", FUTURE ONCOLOGY, FUTURE MEDICINE LTD., LONDON, GB, (20050101), vol. 1, no. 1, ISSN 1479-6694, pages 37 - 50, XP003001827 [A] 1-16 * table 1 *
	International search	[Y]WO2004065583 (GENOMIC HEALTH INC [US], et al);
		[Y]JP2004151003 (NOGI HIROKO, et al);
		[A]WO2006071843 (CIPHERGEN BIOSYSTEMS INC [US], et al);
		[A]WO02103320 (ROSETTA INPHARMATICS INC [US]);
		[A] - STATHOPOULOU ET AL, "Real-Time Quantification of CK-19 mRNA-Positive Cells in Peripheral Blood of Breast Cancer Patients using the Lightcycler System", CLINICAL CANCER RESEARCH, (200311), vol. 9, no. 14, pages 5145 - 5151, XP002407125
		[A] - CHEN ET AL, "Simultaneous detection of multiple mRNA markers CK19, CEA, c-Met, Her2/neu and hMAM with membrane array, an innovative technique with a great potential for breast cancer diagnosis", CANCER LETTERS, (20060828), vol. 240, no. 2, pages 279 - 288, XP005575557 DOI: http://dx.doi.org/10.1016/j.canlet.2005.09.017

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p